Dementia with lewy bodies: diagnosis and management for primary care providers
- PMID: 22295275
- PMCID: PMC3267516
- DOI: 10.4088/PCC.11r01190
Dementia with lewy bodies: diagnosis and management for primary care providers
Abstract
Objective: The purpose of this review is to aid primary care providers in distinguishing dementia with Lewy bodies (DLB) from Alzheimer's disease and from Parkinson's disease with dementia. Differentiating these entities has important treatment implications.
Data sources: A PubMed search was undertaken using the keywords Lewy body dementia, dementia with Lewy bodies, and Lewy body disease. There were no date restrictions. Only articles in the English language were reviewed. References of selected articles were reviewed for additional sources.
Data selection and extraction: Initially, 2,967 articles were retrieved. All 3 authors participated in data selection and extraction. Articles were further selected for content specific to epidemiology, clinical presentation, diagnostic studies, treatment, and prognosis. For articles with repetitive information, the most current article was used. This resulted in a total of 62 articles included in the review.
Data synthesis: Dementia with Lewy bodies is the second leading cause of dementia after Alzheimer's disease. The core symptoms of DLB, including cognitive fluctuations, visual hallucinations, and parkinsonism, may not always be present as a triad, and clinicians may be unaware of associated symptoms. Thus, this diagnosis is frequently missed by primary care providers. Often, DLB is misdiagnosed as Alzheimer's disease, Parkinson's disease, or a primary psychiatric illness. Treatments for DLB include cholinesterase inhibitors and N-methyl-D-aspartate antagonists. Antipsychotics should be avoided or used with caution.
Conclusions: Dementia with Lewy bodies is an often missed diagnosis. Symptoms are often attributed to other disorders. A high clinical suspicion is helpful in accurate diagnosis, and presence of any of the core symptoms should initiate clinical suspicion of DLB. Distinguishing DLB from other disorders has important treatment implications.
Similar articles
-
Dementia with lewy bodies: therapeutic opportunities and pitfalls.Consult Pharm. 2006 Jul;21(7):563-75. doi: 10.4140/tcp.n.2006.563. Consult Pharm. 2006. PMID: 16934009 Review.
-
Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.J Neural Transm (Vienna). 2018 Apr;125(4):615-650. doi: 10.1007/s00702-017-1821-9. Epub 2017 Dec 8. J Neural Transm (Vienna). 2018. PMID: 29222591 Review.
-
Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?BMC Med. 2018 Mar 6;16(1):34. doi: 10.1186/s12916-018-1016-8. BMC Med. 2018. PMID: 29510692 Free PMC article.
-
Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe.Brain. 2002 Feb;125(Pt 2):391-403. doi: 10.1093/brain/awf033. Brain. 2002. PMID: 11844739
-
Neurocognitive Deficits Distinguishing Mild Dementia with Lewy Bodies from Mild Alzheimer's Disease are Associated with Parkinsonism.J Alzheimers Dis. 2016 Jun 30;53(4):1277-85. doi: 10.3233/JAD-160294. J Alzheimers Dis. 2016. PMID: 27372647
Cited by
-
Dementia with Lewy bodies - from scientific knowledge to clinical insights.Nat Rev Neurol. 2019 Feb;15(2):103-112. doi: 10.1038/s41582-018-0107-7. Nat Rev Neurol. 2019. PMID: 30559465 Review.
-
Synuclein Motor Dysfunction Composite Scale for the Discrimination of Dementia With Lewy Bodies From Alzheimer's Disease.Front Aging Neurosci. 2022 May 19;14:920591. doi: 10.3389/fnagi.2022.920591. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35663565 Free PMC article.
-
Ethnopharmacological Approaches for Dementia Therapy and Significance of Natural Products and Herbal Drugs.Front Aging Neurosci. 2018 Feb 12;10:3. doi: 10.3389/fnagi.2018.00003. eCollection 2018. Front Aging Neurosci. 2018. PMID: 29483867 Free PMC article. Review.
-
Differences in Retinal and Choroidal Microvasculature and Structure in Dementia With Lewy Bodies Compared With Normal Cognition.J Vitreoretin Dis. 2023 Nov 15;8(1):67-74. doi: 10.1177/24741264231206607. eCollection 2024 Jan-Feb. J Vitreoretin Dis. 2023. PMID: 38223776 Free PMC article.
-
Confirmation of 123I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders.J Nucl Med. 2020 Nov;61(11):1628-1635. doi: 10.2967/jnumed.119.239418. Epub 2020 Mar 20. J Nucl Med. 2020. PMID: 32198310 Free PMC article.
References
-
- Aarsland D., Rongve A., Nore S.P., et al. Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord. 2008;26(5):445–452. - PubMed
-
- McKeith I.G., Dickson D.W., Lowe J., et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–1872. - PubMed
-
- McKeith I.G., Galasko D., Kosaka K., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113–1124. PubMed. - PubMed
LinkOut - more resources
Full Text Sources